6 doctors weighed in:

Dad has advanced prostate cancer with bone metastasis. After orchirectomy, psa down from 270 to 10. Shall he start zometa or xgeva (denosumab)? Which is better?

6 doctors weighed in
2 doctors agree

In brief: Bones

Xgeva (denosumab) has less side effect profile in my opinion.

In brief: Bones

Xgeva (denosumab) has less side effect profile in my opinion.
Dr. Richard Sarle
Dr. Richard Sarle
Thank
Dr. Uma Swamy
Radiation Oncology
1 doctor agrees

In brief: See Below

Use of bisphosphanates for your dad can be controversial.
Here is an excerpt from a recent review article on www.cancernetwork.com which you can use to discuss with your father's doctor to decide what is best for your dad. http://www.cancernetwork.com/bone-metastases/content/article/10165/105118.

In brief: See Below

Use of bisphosphanates for your dad can be controversial.
Here is an excerpt from a recent review article on www.cancernetwork.com which you can use to discuss with your father's doctor to decide what is best for your dad. http://www.cancernetwork.com/bone-metastases/content/article/10165/105118.
Dr. Uma Swamy
Dr. Uma Swamy
Thank
1 comment
Dr. James Gulley
Neither Zoledronate nor denosumab are approved for prostate cancer that has not progressed on the initial hormonal therapy. I would recommend reviewing with the physician the risks and benefits of doing so. In general, I would wait until the PSA starts to progress. And decrease exposure to these drugs that can have side effects.
Dr. James Gulley
Internal Medicine - Hematology & Oncology

In brief: Off label

Neither zoledronate nor Denosumab is approved for disease that has not progressed on initial hormonal therapy.
I would recommend waiting until disease progression and thus avoid potential side effects from these treatments.

In brief: Off label

Neither zoledronate nor Denosumab is approved for disease that has not progressed on initial hormonal therapy.
I would recommend waiting until disease progression and thus avoid potential side effects from these treatments.
Dr. James Gulley
Dr. James Gulley
Thank
Dr. Julio Hajdenberg
Internal Medicine - Hematology & Oncology

In brief: Either

Xgeva (denosumab) does have some advantages over zometa: quicker administration and no kidney side effects.
It is associated with fewer bone complications from cancer than zometa. On the other hand, zometa is now generic, meaning that is a lot cheaper. Neither is a curative treatment for prostate cancer and they are both considered adjunct treatments. Thes small differences may or may not justify its use.

In brief: Either

Xgeva (denosumab) does have some advantages over zometa: quicker administration and no kidney side effects.
It is associated with fewer bone complications from cancer than zometa. On the other hand, zometa is now generic, meaning that is a lot cheaper. Neither is a curative treatment for prostate cancer and they are both considered adjunct treatments. Thes small differences may or may not justify its use.
Dr. Julio Hajdenberg
Dr. Julio Hajdenberg
Thank
Get help from a real doctor now
Dr. Buck Parker
Board Certified, Surgery
13 years in practice
468K people helped
Continue
108,000 doctors available
Read more answers from doctors